---
title: "PathAI Review (2026) - Ratings, Output Quality & Pricing - AI Software Review"
name: "PathAI"
slug: "pathai"
canonical_url: "https://www.aisoftwarereview.org/reviews/pathai/"
category: "AI Healthcare & Medical"
category_slug: "ai-healthcare-medical"
website_url: "https://pathai.com"
pricing_model: "Clinical / Pharma"
starting_price: "Enterprise Contract"
total_score: 8.1
tier: "Great"
ratings:
  output_quality: 8.4
  total_value: 7.9
  feature_depth: 8.4
  ease_of_use: 7.8
last_updated: "2026-03"
---

# PathAI - AI Software Review & Benchmark

> **AI-powered pathology platform improving diagnostic accuracy and drug development in cancer pathology.**

- **Composite Score:** **8.1 / 10** (Great)
- **Category:** [AI Healthcare & Medical](https://www.aisoftwarereview.org/categories/ai-healthcare-medical/)
- **Pricing:** Clinical / Pharma (Starting at Enterprise Contract)
- **Official Website:** [https://pathai.com](https://www.aisoftwarereview.org/r/pathai/)
- **Evaluated:** 2026-03 (Independent Review • Zero Pay-to-Play)

---

## Evaluation Scorecard

Our composite ratings weight real-world **Output Quality (35%)** and **Total Value (35%)** above venture hype.

| Evaluation Metric | Weight | Score | Description |
| :--- | :---: | :---: | :--- |
| **Output Quality** | **35%** | **8.4 / 10** | Accuracy, prompt adherence, coherence, and production readiness of outputs |
| **Total Value** | **35%** | **7.9 / 10** | Transparent pricing, unit economics, free tier utility, and ROI |
| **Feature Depth** | **15%** | **8.4 / 10** | Enterprise controls, API ecosystem, integrations, and workflow customization |
| **Ease of Use** | **15%** | **7.8 / 10** | UI responsiveness, onboarding ergonomics, documentation, and user friction |
| **Overall Composite Score** | **100%** | **8.1 / 10** | **Great** |

---

## Verdict & Editorial Summary

The premier computational pathology platform for cancer diagnosis and pharmaceutical clinical trials.

---

## Overview & Field Findings

PathAI applies deep learning to digitized histology slides, assisting pathologists in accurately detecting cancerous cells, scoring biomarkers, and accelerating biopharma drug discovery.

---

## Key Features & Capabilities

- AISight digital pathology image analysis platform
- Accurate quantification of tumor-infiltrating lymphocytes and PD-L1 biomarkers
- Reduces diagnostic variability across pathology interpretations

---

## Pricing & Commercial Terms

Enterprise licensing for clinical pathology labs and pharmaceutical biopharma research partners.


### Pricing Plans Breakdown

| Plan Name | Price | Billing Cycle | Highlights |
| :--- | :--- | :--- | :--- |
| **AISight** | Enterprise | annual | Digital pathology viewer; Tumor microenvironment analysis; Biomarker scoring |


---

## Pros & Cons

### Strengths
- **+** Unrivaled precision in quantifying tumor cellular boundaries
- **+** Reduces inter-pathologist diagnostic variability
- **+** Strong biopharmaceutical partnerships

### Trade-offs & Limitations
- **-** Requires high-resolution digital whole-slide scanners

---

## Deployment Recommendations

### Ideal For
- Pathology laboratories, cancer institutes, and biopharma drug developers

### Not Recommended For
- Consumer diagnostics

---

*Published by AI Software Review ([www.aisoftwarereview.org](https://www.aisoftwarereview.org/)). All ratings are determined by standardized prompt testing without commercial compensation or pay-to-play sponsorships.*